Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO.

被引：1

作者：

Terpos, Evangelos

Dimopoulos, Meletios A.

Boccadoro, Mario

Delimpasi, Sosana

Beksac, Meral

Katodritou, Eirini

Moreau, Philippe

Baldini, Luca

Symeonidis, Argiris

Bila, Jelena

Oriol, Albert

Mateos, Maria-Victoria

Einsele, Hermann

Orfanidis, Ioannis

Gries, Katharine S.

Fastenau, John

Kampfenkel, Tobias

Qiu, Yanping

Amin, Himal

Sonneveld, Pieter

机构：

[1] Natl & Kapodistrian Univ Athens, Athens, Greece

[2] Univ Torino, Turin, Italy

[3] Gen Hosp Evangelismos, Athens, Greece

[4] Ankara Univ, Ankara, Turkey

[5] Theagen Canc Hosp, Thessaloniki, Greece

[6] Univ Hosp, Hotel Dieu, Hematol, Nantes, France

[7] Univ Milan, Milan, Italy

[8] Univ Patras, Patras, Greece

[9] Univ Belgrade, Belgrade, Serbia

[10] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

[11] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Barcelona, Spain

[12] Univ Hosp Salamanca, IBSAL, Canc Res Ctr IBMCC USAL CSIC, Salamanca, Spain

[13] Wurzburg Univ, Med Ctr, Wurzburg, Germany

[14] Hlth Data Specialists SA, Dublin, Ireland

[15] Janssen Res & Dev LLC, Raritan, NJ USA

[16] Janssen Res & Dev LLC, Leiden, NJ, Netherlands

[17] Janssen Res & Dev LLC, Beijing, Peoples R China

[18] Erasmus Univ, Med Ctr, Canc Inst, Rotterdam, Netherlands

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.8046

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8046

引用

页数：3

共 50 条

[31] USE OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES/PATIENT-REPORTED OUTCOMES (PROS) IN RARE HEMATOLOGICAL DISEASE (RHD) HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS
Thakur, D.
Islam, S.
Igbelina, C. D.
Patel, V
Zhou, M.
Dabirvaziri, P.
VALUE IN HEALTH, 2022, 25 (12) : S304 - S304
[32] HEALTH-RELATED QUALITY OF LIFE PATIENT-REPORTED OUTCOMES IN SCHIZOPHRENIA
Millier, A.
Clay, E.
Chauhan, D.
Toumi, M.
VALUE IN HEALTH, 2012, 15 (07) : A342 - A342
[33] APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Einsele, H.
Dimopoulos, M.
Terpos, E.
Boccadoro, M.
Delimpasi, S.
Beksac, M.
Katodritou, E.
Moreau, P.
Baldini, L.
Symeonidis, A.
Bila, J.
Oriol, A.
Mateos, M. -, V
Orfanidis, I
Ahmadi, T.
Ukropec, J.
Kampfenkel, T.
Schecter, J.
Qiu, Y.
Amin, H.
Vermeulen, J.
Carson, R.
Sonneveld, P.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 178 - 178
[34] Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
Delforge, Michel
Shah, Nina
Miguel, Jesus San F.
Braverman, Julia
Dhanda, Devender S.
Shi, Ling
Guo, Shien
Yu, Peiwen
Liao, Weiqin
Campbell, Timothy B.
Munshi, Nikhil C.
BLOOD ADVANCES, 2022, 6 (04) : 1309 - 1318
[35] Health-related quality of life (HRQoL) patient-reported outcomes (PROs) and survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
David, Lorente
Lozano, Rebeca
de Velasco, Guillermo
Romero-Laorden, Nuria
Castro, Elena
Rodrigo-Aliaga, Miguel
Sanchez, Angel L.
Di Capua, Carlos
Sanchez-Hernandez, Alfredo
Olmos, David
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[36] Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).
Delforge, Michel
Patel, Krina K.
Eliason, Laurie
Dhanda, Devender
Shi, Ling
Guo, Shien
Marshall, Thomas
Arnulf, Bertrand
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie Scott
Giralt, Sergio
Einsele, Hermann
Ailawadhi, Sikander
McKiver, Mihaela Popa
Cook, Mark
Rodriguez-Otero, Paula
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
Schjesvold, Fredrik H.
Ludwig, Heinz
Delimpasi, Sossana
Robak, Pawel
Coriu, Daniel
Tomczak, Waldemar
Pour, Ludek
Spicka, Ivan
Dimopoulos, Meletios-Athanasios
Masszi, Tamas
Chernova, Natalia G.
Sandberg, Anna
Thuresson, Marcus
Norin, Stefan
Bakker, Nicolaas A.
Mateos, Maria-Victoria
Richardson, Paul G.
Sonneveld, Pieter
REVISTA CHILENA DE LITERATURA, 2024, (109): : 2331 - 2336
[38] Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
Schjesvold, Fredrik H.
Ludwig, Heinz
Delimpasi, Sossana
Robak, Pawel
Coriu, Daniel
Tomczak, Waldemar
Pour, Ludek
Spicka, Ivan
Dimopoulos, Meletios-Athanasios
Masszi, Tamas
Chernova, Natalia G.
Sandberg, Anna
Thuresson, Marcus
Norin, Stefan
Bakker, Nicolaas A.
Mateos, Maria-Victoria
Richardson, Paul G.
Sonneveld, Pieter
HAEMATOLOGICA, 2024, 109 (07) : 2331 - 2336
[39] Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Dimopoulos, Meletios A.
Terpos, Evangelos
Boccadoro, Mario
Delimpasi, Sosana
Beksac, Meral
Katodritou, Eirini
Moreau, Philippe
Baldini, Luca
Symeonidis, Argiris
Bila, Jelena
Oriol, Albert
Mateos, Maria-Victoria
Einsele, Hermann
Orfanidis, Ioannis
Ahmadi, Tahamtan
Ukropec, Jon
Kampfenkel, Tobias
Schecter, Jordan
Qiu, Yanping
Amin, Himal
Vermeulen, Jessica
Carson, Robin
Sonneveld, Pieter
BLOOD, 2020, 136
[40] A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO
Terpos, E.
Dimopoulos, M. A.
Kastritis, E.
Schecter, J. M.
Ukropec, J.
Smith, E.
Sonneveld, P.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →